DONALD CLARK: Open Payments
NPI 1386669570 · GARDEN CITY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,173 in 62 payments from 13 companies in 2025. Trend: 2023 $3,035 · 2024 $1,211 · 2025 $1,173
Food & beverage: $1,173
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 15 | $249 |
| Merck Sharp & Dohme LLC | 8 | $189 |
| Novo Nordisk Inc | 9 | $152 |
| GlaxoSmithKline, LLC. | 5 | $107 |
| Amgen Inc. | 4 | $73 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $70 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| ABBVIE INC. | 3 | $53 |
| Esperion Therapeutics, Inc. | 3 | $52 |
Products named: MOUNJARO, VERQUVO, TRELEGY ELLIPTA, Rybelsus, OTEZLA, Kerendia, KISUNLA, LEQVIO.
Industry payments across MI — which companies pay providers there.
